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Author’s response to ‘CAP
and HCAP are different?
An unresolved question’
Dear Editor,
We thank the authors for the interest in
our recent publication and for their useful
comments.
Unfortunately we consider the compari-
son with the publication from Giannella
et al1 poorly appropriate in many aspects.
The main strength of our work is the
multicentre prospective case–control study
design (match by age, gender and period of
hospitalisation). Although severity scores
were not used for matching, we considered
this design the most appropriate to describe
healthcare-associated pneumonia (HCAP)
features. In fact, the Giannella group
performed an observational prospective
study only on patients admitted to internal
medicine departments: these elements
(study design and patients) could justify a
different population composition and,
consequently, different microbiological and
clinical ﬁndings. In fact, in comparison
with our HCAP patients, this population
(Giannella et al1) clearly showed older
age (mean age; Giannella: 83 years vs
Polverino: 78.8 years), poorer functional
status (mean Barthel score; 30 vs 58) and
more aspiration risk (50% vs 39%).
We have also reanalysed the number of
comorbidities across the sites of care
(respiratory and internal medicine depart-
ments) of our study. We observed that
cases (HCAP) did systematically show
more comorbidities than controls (CAP) in
all departments. Moreover, the mean
number of comorbidities of HCAP admit-
ted to respiratory departments (mean±SD,
2.5±1.9) was similar to that of HCAP
patients admitted to internal medicine
(2.7±1.6) departments.
Similarly, the modiﬁed Charlson index
for comorbidities was systematically
higher for HCAP in comparison with
CAP independently of the site of care.
HCAP cases showed similar Charlson
index in both respiratory (mean±SD, 2.5
±1.6) and internal medicine (mean±SD,
2.5±1.8) departments.
In comparison with our study, the
HCAP population from the Giannella
study presents poorer functional status,
more risk factors for CAP severity and for
MDR pathogens. For these reasons in our
opinion, the work of Giannella et al does
not fully represent the general population
unlike our study that includes patients
from all medical services potentially
attending pneumonia patients.
On the other hand, we agree with
Falcone et al2 about the fact that BAL is
the best diagnostic option for pneumonia;
for this reason, we included BAL in our
microbiological panel. Unfortunately a
number of reasons did not consent us to
perform a minimal number of BAL: (1)
the bad clinical condition of our patients
at admission (particularly HCAP), (2) the
usual unavailability of bronchoscopy at
the emergency departments and (3) the
frequent patients’ rejection of bronchos-
copy. Unfortunately these difﬁculties
reﬂect the real world of clinical practice.
Nonetheless, our microbiological results
are fully coherent with other studies from
Spain3 4 and UK,5 while the assessment of
MDR risk should possibly be based on
speciﬁc clinical factors (ie, previous anti-
biotic therapy, etc.) in any population
(including CAP6) rather than on the
HCAP label that has shown poor predict-
ive value for it.7
For all these reasons, we think that
current guidelines for CAP are still valid for
HCAP in Europe, but risk factors for MDR
should still be considered individually.
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